COMPANY RESEARCHUses AI, physics-based simulation, peptide chemistry, and oral formulation development for oral immunology and cardiometabolic peptides; operates in Shanghai and Pennsylvania.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Uses AI, physics-based simulation, peptide chemistry, and oral formulation development for oral immunology and cardiometabolic peptides; operates in Shanghai and Pennsylvania.
2026-03-26: Pinnacle raises $89 million Series B to advance oral peptide programs
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Oral peptide programs in immunology | Not disclosed · Asthma / COPD / IBD / atopic dermatitis | 未披露 | Quantitative human results not confirmed in this review |
| Oral peptide programs in cardiometabolic disease | Not disclosed · Obesity / cardiovascular disease | 未披露 | Quantitative human results not confirmed in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Pinnacle Medicines closed an $89 million Series B co-led by LAV and Foresite Capital, bringing disclosed funding to $134 million. Proceeds support oral peptide programs toward clinical proof of concept, initially in immunology and cardiometabolic disease, alongside expansion of AI and physics-based discovery capabilities. The announcement does not provide new human efficacy results.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
